URGN News & Events

UroGen Pharma announced the grants of inducement restricted stock units to 11 new employees in connection with their employment with UroGen. These new team members will support the ongoing commercialization of Jelmyto for pyelocalyceal solution and Zusdur for intravesical solution, UroGen's only approved products, and the continued development of UroGen's pipeline.

Guidance for full-year 2026 net product sales for Jelmyto are expected to be in the range of $97 million to $101 million. This implies a year-over-year growth rate of approximately 3% to 7% over the $94 million of Jelmyto sales reported in 2025.

Reports Q4 revenue $37.837M, consensus $39.92M. "2025 was a tremendously successful and transformative year for UroGen, highlighted by the FDA approval and commercial launch of ZUSDURI, the first and only approved medicine for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer," said Liz Barrett, President and Chief Executive Officer of UroGen. "2026 is a pivotal year for the ZUSDURI launch, and we are encouraged by the early post-J Code trajectory. As expected, we are seeing an acceleration across key launch indicators, including physician uptake and adoption. We believe ZUSDURI is well positioned to address a significant unmet need and represents a greater than $1 billion peak sales opportunity."